Evidence map›Paper›PMID 31456229›Full record

ArticleDevelopmental psychobiology2020

Brief and extended abstinence from chronic oral methylphenidate treatment produces reversible behavioral and physiological effects.

Leanna Kalinowski, Carly Connor, Rathini Somanesan, Emily Carias, Kaleigh Richer, Lauren Smith, Connor Martin, Macauley Mackintosh, Daniel Popoola, Michael Hadjiargyrou and 2 more

Open access · greenAbstract read
In one paragraph

Article in Developmental psychobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Frontiers in pharmacology · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Leanna KalinowskiDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA.
Carly ConnorDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA.
Rathini SomanesanDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA.
Emily CariasDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA.
Kaleigh RicherDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA.
Lauren SmithDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA.
Connor MartinDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA.
Macauley MackintoshDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA.
Daniel PopoolaDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA.
Michael HadjiargyrouDepartment of Life Sciences, New York Institute of Technology, Old Westbury, NY, USA.
David E KomatsuDepartment of Orthopedics, Stony Brook University, Stony Brook, NY, USA.
Panayotis K ThanosDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA.ORCID 0000-0002-5663-3478
Jacobs Institute · USNew York Institute of Technology · USStony Brook Medicine · US

Funding

RESEARCH TRAINING ON ALCOHOL ETIOLOGY AND TREATMENTT32AA007583 · NIAAA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Gregory G Homish, KENNETH E LEONARD · 2000 to 2026
$8.5M
Skeletal Effects of MethylphenidateR01HD070888 · NICHD · STATE UNIVERSITY NEW YORK STONY BROOK · PI KOMATSU, DAVID E · 2013 to 2017
$1.6M
NIAAA NIH HHS T32 AA007583NICHD NIH HHS R01 HD070888
6 · The paper itself

Abstract

Methylphenidate (MP) is a commonly prescribed psychostimulant to individuals with Attention Deficit Hyperactivity Disorder, and is often used illicitly among healthy individuals with intermittent breaks to coincide with breaks from school. This study examined how intermittent abstinence periods impact the physiological and behavioral effects of chronic oral MP self-administration in rats, and whether these effects persist following prolonged abstinence from the drug. Rats were treated orally with water, low-dose (LD), or high-dose (HD) MP, beginning at PND 28. This daily access continued for three consecutive weeks followed by a 1-week abstinence; after three repeats of this cycle, there was a 5-week abstinence period. Throughout the study, we examined body weight, food intake, locomotor activity, and anxiety- and depressive-like behaviors. During the treatment phase, HD MP decreased body weight, food intake, and depressive- and anxiety-like behaviors, while it increased locomotor activity. During intermittent abstinence, the effects of MP on locomotor activity were eliminated. During prolonged abstinence, most of the effects of HD MP were ameliorated to control levels, with the exception of weight loss and anxiolytic effects. These findings suggest that intermittent exposure to chronic MP causes physiological and behavioral effects that are mostly reversible following prolonged abstinence.

Indexed as

AnimalsAttention Deficit Disorder with HyperactivityBehavior, AnimalBody WeightCentral Nervous System StimulantsDisease Models, AnimalEatingLocomotionMaleMethylphenidateRatsRats, Sprague-DawleyCentral Nervous System StimulantsMethylphenidateanxietyAttention Deficit Hyperactivity Disordermethylphenidatepsychostimulantritalin

Identifiers

PMID31456229
PMCPMC7028498
OpenAlexW2971061070

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.